Literature DB >> 27802507

To Treat or Not to Treat (to Target) in Gout.

Tuhina Neogi1, Ted R Mikuls1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27802507      PMCID： PMC5304916          DOI： 10.7326/M16-2401

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  8 in total

1.  2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Authors:  Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

2.  Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study.

Authors:  Fernando Perez-Ruiz; Joana Atxotegi; Iñaki Hernando; Marcelo Calabozo; Joan M Nolla
Journal:  Arthritis Rheum       Date:  2006-10-15

3.  Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Authors:  John S Sundy; Herbert S B Baraf; Robert A Yood; N Lawrence Edwards; Sergio R Gutierrez-Urena; Edward L Treadwell; Janitzia Vázquez-Mellado; William B White; Peter E Lipsky; Zeb Horowitz; William Huang; Allan N Maroli; Royce W Waltrip; Steven A Hamburger; Michael A Becker
Journal:  JAMA       Date:  2011-08-17       Impact factor: 56.272

4.  Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.

Authors:  Lisa K Stamp; William J Taylor; Peter B Jones; Jo L Dockerty; Jill Drake; Christopher Frampton; Nicola Dalbeth
Journal:  Arthritis Rheum       Date:  2012-08

5.  Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study.

Authors:  Tuhina Neogi; David J Hunter; Christine E Chaisson; Donald Allensworth-Davies; Yuqing Zhang
Journal:  J Rheumatol       Date:  2005-11-01       Impact factor: 4.666

6.  A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.

Authors:  Fernando Perez-Ruiz; Ana Maria Herrero-Beites; Loreto Carmona
Journal:  Arthritis Rheum       Date:  2011-12

Review 7.  Diagnosis of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline.

Authors:  Sydne J Newberry; John D FitzGerald; Aneesa Motala; Marika Booth; Margaret A Maglione; Dan Han; Abdul Tariq; Claire E O'Hanlon; Roberta Shanman; Whitney Dudley; Paul G Shekelle
Journal:  Ann Intern Med       Date:  2016-11-01       Impact factor: 25.391

Review 8.  Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline.

Authors:  Paul G Shekelle; Sydne J Newberry; John D FitzGerald; Aneesa Motala; Claire E O'Hanlon; Abdul Tariq; Adeyemi Okunogbe; Dan Han; Roberta Shanman
Journal:  Ann Intern Med       Date:  2016-11-01       Impact factor: 25.391
  8 in total
  8 in total

1.  Editorial: The Evolving Art and Science of American College of Rheumatology Guidelines.

Authors:  Jinoos Yazdany; Liron Caplan; John Fitzgerald; Gabriela Schmajuk
Journal:  Arthritis Rheumatol       Date:  2018-11-30       Impact factor: 10.995

Review 2.  Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN).

Authors:  Nicola Dalbeth; Thomas Bardin; Michael Doherty; Frédéric Lioté; Pascal Richette; Kenneth G Saag; Alexander K So; Lisa K Stamp; Hyon K Choi; Robert Terkeltaub
Journal:  Nat Rev Rheumatol       Date:  2017-08-10       Impact factor: 20.543

Review 3.  Asymptomatic hyperuricaemia: a silent activator of the innate immune system.

Authors:  Leo A B Joosten; Tania O Crişan; Petter Bjornstad; Richard J Johnson
Journal:  Nat Rev Rheumatol       Date:  2019-12-10       Impact factor: 20.543

4.  Understanding the patient voice in gout: a quantitative study conducted in Europe.

Authors:  Marc De Meulemeester; Elsa Mateus; Hilda Wieberneit-Tolman; Neil Betteridge; Lucy Ireland; Gudula Petersen; Nina Jeanette Maske; Tim L Jansen; Fernando Perez-Ruiz
Journal:  BJGP Open       Date:  2020-05-01

Review 5.  Moving the Needle: Improving the Care of the Gout Patient.

Authors:  Jon Golenbiewski; Robert T Keenan
Journal:  Rheumatol Ther       Date:  2019-03-02

6.  Evaluation of Proposed Criteria for Remission and Evidence-Based Development of Criteria for Complete Response in Patients With Chronic Refractory Gout.

Authors:  Naomi Schlesinger; N Lawrence Edwards; Puja P Khanna; Anthony E Yeo; Peter E Lipsky
Journal:  ACR Open Rheumatol       Date:  2019-05-23

Review 7.  When underlying biology threatens the randomization principle - initial gout flares of urate-lowering therapy.

Authors:  Hyon K Choi; Yuqing Zhang; Nicola Dalbeth
Journal:  Nat Rev Rheumatol       Date:  2022-07-25       Impact factor: 32.286

8.  Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality.

Authors:  Fernando Pérez Ruiz; Pascal Richette; Austin G Stack; Ravichandra Karra Gurunath; Ma Jesus García de Yébenes; Loreto Carmona
Journal:  RMD Open       Date:  2019-10-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.